NASDAQ:RGLS - Regulus Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.72 +0.01 (+1.41 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$0.72
Today's Range$0.72 - $0.72
52-Week Range$0.63 - $1.60
Volume240 shs
Average Volume178,076 shs
Market Capitalization$75.11 million
P/E Ratio-0.75
Dividend YieldN/A
Beta1.72

About Regulus Therapeutics (NASDAQ:RGLS)

Regulus Therapeutics logoRegulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.

Receive RGLS News and Ratings via Email

Sign-up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:RGLS
CUSIP75915K10
Phone858-202-6300

Debt

Debt-to-Equity RatioN/A
Current Ratio1.66
Quick Ratio1.66

Price-To-Earnings

Trailing P/E Ratio-0.75
Forward P/E Ratio-1.18
P/E GrowthN/A

Sales & Book Value

Annual Sales$70,000.00
Price / Sales1,073.01
Cash FlowN/A
Price / CashN/A
Book Value$0.22 per share
Price / Book3.27

Profitability

EPS (Most Recent Fiscal Year)($0.96)
Net Income$-71,900,000.00
Net Margins-94,318.05%
Return on Equity-214.48%
Return on Assets-92.85%

Miscellaneous

Employees63
Outstanding Shares104,320,000

Regulus Therapeutics (NASDAQ:RGLS) Frequently Asked Questions

What is Regulus Therapeutics' stock symbol?

Regulus Therapeutics trades on the NASDAQ under the ticker symbol "RGLS."

How were Regulus Therapeutics' earnings last quarter?

Regulus Therapeutics Inc. (NASDAQ:RGLS) announced its quarterly earnings data on Thursday, May, 10th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, meeting the consensus estimate of ($0.15). The biopharmaceutical company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million. Regulus Therapeutics had a negative net margin of 94,318.05% and a negative return on equity of 214.48%. View Regulus Therapeutics' Earnings History.

When is Regulus Therapeutics' next earnings date?

Regulus Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Regulus Therapeutics.

What price target have analysts set for RGLS?

6 analysts have issued 1-year target prices for Regulus Therapeutics' shares. Their forecasts range from $1.00 to $3.00. On average, they expect Regulus Therapeutics' share price to reach $1.90 in the next year. View Analyst Ratings for Regulus Therapeutics.

What are Wall Street analysts saying about Regulus Therapeutics stock?

Here are some recent quotes from research analysts about Regulus Therapeutics stock:
  • 1. According to Zacks Investment Research, "Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. " (5/18/2018)
  • 2. Needham & Company LLC analysts commented, "Regulus reported 3Q17 financial results last wk and we met w/ mgmt for an update today. Both planned clinical trials of RG-012 in Alport Syndrome pts are now underway and an IND has been submitted for RGLS4326 in Autosomal Dominant Polycystic Kidney Disease. Mgmt has identified male X-linked Alport Syndrome as target pt population for clinical development going forward, due to rapid and homogeneous disease progression. We expect top-line results from 10- patient RG-012 biopsy trial early next yr and from 40-patient RG-012 HERA Phase 2 efficacy trial in early 2019. Maintain HOLD, awaiting more data from lead RG-012 program, but also note encouraging progression of platform/ pipeline behind it." (11/14/2017)

Who are some of Regulus Therapeutics' key competitors?

Who are Regulus Therapeutics' key executives?

Regulus Therapeutics' management team includes the folowing people:
  • Mr. Joseph P. Hagan, Chief Exec. Officer, Pres and Director (Age 49)
  • Dr. Timothy Michael Wright M.D., Ph.D., Chief R&D Officer (Age 62)
  • Mr. Daniel R. Chevallard CPA, Chief Financial Officer
  • Ms. Allison Wey, VP of Investor Relations & Corp. Communications
  • Mr. Christopher Aker J.D., VP of Legal Affairs & Corp. Sec.

Has Regulus Therapeutics been receiving favorable news coverage?

Media coverage about RGLS stock has been trending positive this week, according to Accern Sentiment. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Regulus Therapeutics earned a news sentiment score of 0.33 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 46.95 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are Regulus Therapeutics' major shareholders?

Regulus Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Point72 Asset Management L.P. (0.71%) and A.R.T. Advisors LLC (0.16%). Company insiders that own Regulus Therapeutics stock include Daniel R Chevallard, Joseph P Hagan, Stelios Papadopoulos and William H Rastetter. View Institutional Ownership Trends for Regulus Therapeutics.

Which major investors are selling Regulus Therapeutics stock?

RGLS stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P.. View Insider Buying and Selling for Regulus Therapeutics.

Which major investors are buying Regulus Therapeutics stock?

RGLS stock was acquired by a variety of institutional investors in the last quarter, including A.R.T. Advisors LLC. Company insiders that have bought Regulus Therapeutics stock in the last two years include Daniel R Chevallard, Joseph P Hagan, Stelios Papadopoulos and William H Rastetter. View Insider Buying and Selling for Regulus Therapeutics.

How do I buy shares of Regulus Therapeutics?

Shares of RGLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Regulus Therapeutics' stock price today?

One share of RGLS stock can currently be purchased for approximately $0.72.

How big of a company is Regulus Therapeutics?

Regulus Therapeutics has a market capitalization of $75.11 million and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-71,900,000.00 in net income (profit) each year or ($0.96) on an earnings per share basis. Regulus Therapeutics employs 63 workers across the globe.

How can I contact Regulus Therapeutics?

Regulus Therapeutics' mailing address is 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-202-6300 or via email at [email protected]


MarketBeat Community Rating for Regulus Therapeutics (RGLS)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  347 (Vote Outperform)
Underperform Votes:  164 (Vote Underperform)
Total Votes:  511
MarketBeat's community ratings are surveys of what our community members think about Regulus Therapeutics and other stocks. Vote "Outperform" if you believe RGLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGLS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Regulus Therapeutics (NASDAQ:RGLS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Regulus Therapeutics in the last 12 months. Their average twelve-month price target is $1.90, suggesting that the stock has a possible upside of 163.89%. The high price target for RGLS is $3.00 and the low price target for RGLS is $1.00. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.332.332.432.29
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $1.90$2.10$2.70$2.8750
Price Target Upside: 163.89% upside162.50% upside92.86% upside215.93% upside

Regulus Therapeutics (NASDAQ:RGLS) Consensus Price Target History

Price Target History for Regulus Therapeutics (NASDAQ:RGLS)

Regulus Therapeutics (NASDAQ:RGLS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/17/2018WedbushReiterated RatingOutperform$3.00LowView Rating Details
3/28/2018B. RileyInitiated CoverageNeutral$1.00HighView Rating Details
3/8/2018BMO Capital MarketsSet Price TargetMarket Perform ➝ Hold$1.00HighView Rating Details
1/16/2018Chardan CapitalReiterated RatingNeutralLowView Rating Details
1/5/2018Leerink SwannInitiated CoverageOutperform ➝ Outperform$2.00HighView Rating Details
11/14/2017Needham & Company LLCReiterated RatingHoldN/AView Rating Details
3/3/2017CowenReiterated RatingHoldN/AView Rating Details
3/3/2017Cantor FitzgeraldLower Price TargetBuy$7.00 ➝ $4.00N/AView Rating Details
1/30/2017Wells Fargo & CoDowngradeOutperform ➝ Market PerformN/AView Rating Details
6/28/2016FBR & CoReiterated RatingOutperform$30.00 ➝ $9.00N/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Regulus Therapeutics (NASDAQ:RGLS) Earnings History and Estimates Chart

Earnings by Quarter for Regulus Therapeutics (NASDAQ:RGLS)

Regulus Therapeutics (NASDAQ:RGLS) Earnings Estimates

2018 EPS Consensus Estimate: ($0.67)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.20)($0.13)($0.17)
Q2 20182($0.20)($0.13)($0.17)
Q3 20182($0.20)($0.13)($0.17)
Q4 20182($0.21)($0.13)($0.17)
Q4 20191($0.16)($0.16)($0.16)

Regulus Therapeutics (NASDAQ RGLS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/30/2018($0.15)N/AView Earnings Details
5/10/2018Q1 2018($0.15)($0.15)$0.02 million$0.02 millionViewN/AView Earnings Details
3/7/2018Q4 2017($0.17)($0.14)$0.02 million$0.02 millionViewListenView Earnings Details
11/7/2017Q3 2017($0.18)($0.18)$0.02 million$0.02 millionViewN/AView Earnings Details
8/1/2017Q2 2017($0.31)($0.4060)$0.02 million$0.02 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.33)($0.38)$0.02 million$0.02 millionViewN/AView Earnings Details
3/2/2017Q4 2016($0.37)($0.3780)$0.20 million$0.02 millionViewListenView Earnings Details
11/1/2016Q3 2016($0.39)($0.37)$0.50 million$0.20 millionViewN/AView Earnings Details
8/2/2016Q216($0.38)($0.40)$0.50 million$0.48 millionViewListenView Earnings Details
5/2/2016Q1($0.33)($0.40)$2.25 million$0.49 millionViewListenView Earnings Details
2/22/2016Q415($0.25)($0.14)$5.09 million$10.90 millionViewListenView Earnings Details
11/5/2015Q315($0.37)($0.25)$3.57 million$1.87 millionViewN/AView Earnings Details
8/4/2015Q215($0.29)($0.41)$2.40 million$3.80 millionViewN/AView Earnings Details
5/7/2015($0.26)($0.25)$3.38 million$4.20 millionViewListenView Earnings Details
2/18/2015($0.21)($0.47)$2.24 million$4.22 millionViewListenView Earnings Details
11/5/2014($0.23)($0.23)$2.76 million$1.08 millionViewListenView Earnings Details
8/6/2014Q214($0.19)($0.29)$3.20 million$0.74 millionViewN/AView Earnings Details
5/8/2014($0.14)($0.30)$3.80 million$1.63 millionViewN/AView Earnings Details
2/27/2014($0.13)($0.11)$3.69 million$5.45 millionViewN/AView Earnings Details
11/13/2013Q3 2013($0.16)($0.07)$3.56 million$6.12 millionViewN/AView Earnings Details
8/13/20132Q13($0.14)($0.20)$3.44 million$4.80 millionViewN/AView Earnings Details
5/14/2013Q1 2013($0.09)($0.20)$2.96 million$3.24 millionViewN/AView Earnings Details
2/20/2013Q412($0.08)($0.22)$3.50 million$3.24 millionViewN/AView Earnings Details
11/19/2012Q312($15.98)$3.81 million$2.80 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Regulus Therapeutics (NASDAQ:RGLS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Regulus Therapeutics (NASDAQ RGLS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.80%
Institutional Ownership Percentage: 50.92%
Insider Trading History for Regulus Therapeutics (NASDAQ:RGLS)
Insider Trading History for Regulus Therapeutics (NASDAQ:RGLS)

Regulus Therapeutics (NASDAQ RGLS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/25/2017Daniel R ChevallardCFOBuy54,945$0.91$49,999.9559,415View SEC Filing  
7/25/2017Joseph P HaganInsiderBuy219,780$0.91$199,999.80241,297View SEC Filing  
7/25/2017William H RastetterDirectorBuy274,725$0.91$249,999.75View SEC Filing  
3/22/2017Stelios PapadopoulosDirectorBuy500,000$1.22$610,000.00400,677View SEC Filing  
3/7/2017William H RastetterDirectorBuy250,000$1.15$287,500.00View SEC Filing  
3/3/2016Joseph P HaganCOOBuy10,000$7.19$71,900.0010,000View SEC Filing  
2/23/2016Alnylam Pharmaceuticals, Inc.Major ShareholderSell1,000,000$7.18$7,180,000.004,896,716View SEC Filing  
7/21/2015William H RastetterDirectorBuy100,000$10.17$1,017,000.00View SEC Filing  
7/20/2015William H RastetterDirectorBuy38,765$10.13$392,689.45View SEC Filing  
7/17/2015Isis Pharmaceuticals IncMajor ShareholderSell343,133$10.60$3,637,209.80View SEC Filing  
4/21/2015Kleanthis G XanthopoulosCEOSell200,000$17.15$3,430,000.00View SEC Filing  
4/13/2015Bruce L A CarterDirectorSell20,000$17.66$353,200.00View SEC Filing  
3/5/2015Kleanthis G XanthopoulosCEOSell89,230$20.26$1,807,799.80View SEC Filing  
2/2/2015Kleanthis G XanthopoulosCEOSell5,700$19.61$111,777.00View SEC Filing  
1/29/2015Kleanthis G XanthopoulosCEOSell145,000$18.06$2,618,700.00View SEC Filing  
1/28/2015Neil W GibsonInsiderSell80,000$18.05$1,444,000.00View SEC Filing  
11/28/2014Neil W GibsonInsiderSell2,500$19.30$48,250.00View SEC Filing  
11/3/2014Isis Pharmaceuticals IncMajor ShareholderSell1,279,411$15.94$20,393,811.34View SEC Filing  
10/24/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell113,084$14.02$1,585,437.68View SEC Filing  
10/22/2014Neil W GibsonInsiderSell3,300$14.44$47,652.00View SEC Filing  
10/10/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,000$6.41$12,820.00View SEC Filing  
10/10/2014Isis Pharmaceuticals IncDirectorSell10,050$6.56$65,928.00View SEC Filing  
10/9/2014Isis Pharmaceuticals IncDirectorSell4,750$6.58$31,255.00View SEC Filing  
10/8/2014Isis Pharmaceuticals IncDirectorSell3,300$6.63$21,879.00View SEC Filing  
10/3/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell10,300$6.74$69,422.00View SEC Filing  
10/3/2014Isis Pharmaceuticals IncDirectorSell3,300$6.88$22,704.00View SEC Filing  
10/2/2014Isis Pharmaceuticals IncDirectorSell3,750$6.64$24,900.00View SEC Filing  
10/1/2014Isis Pharmaceuticals IncDirectorSell3,250$6.71$21,807.50View SEC Filing  
9/30/2014Kleanthis G XanthopoulosCEOSell2,300$7.02$16,146.00View SEC Filing  
9/26/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,500$7.04$17,600.00View SEC Filing  
9/26/2014Isis Pharmaceuticals IncDirectorSell8,750$7.13$62,387.50View SEC Filing  
9/25/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,500$7.12$17,800.00View SEC Filing  
9/24/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell3,750$7.19$26,962.50View SEC Filing  
9/19/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell7,700$7.31$56,287.00View SEC Filing  
9/19/2014Isis Pharmaceuticals IncDirectorSell4,100$7.22$29,602.00View SEC Filing  
9/18/2014Isis Pharmaceuticals IncDirectorSell1,500$7.40$11,100.00View SEC Filing  
9/17/2014Isis Pharmaceuticals IncDirectorSell2,100$7.43$15,603.00View SEC Filing  
9/12/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell8,900$7.85$69,865.00View SEC Filing  
9/12/2014Isis Pharmaceuticals IncDirectorSell3,500$7.96$27,860.00View SEC Filing  
9/12/2014Neil W GibsonInsiderSell4,200$8.01$33,642.00View SEC Filing  
9/11/2014Isis Pharmaceuticals IncDirectorSell3,400$7.83$26,622.00View SEC Filing  
9/10/2014Isis Pharmaceuticals IncDirectorSell2,000$7.70$15,400.00View SEC Filing  
9/5/2014Isis Pharmaceuticals IncDirectorSell10,050$7.07$71,053.50View SEC Filing  
8/29/2014Isis Pharmaceuticals IncDirectorSell1,500$6.84$10,260.00View SEC Filing  
8/28/2014Isis Pharmaceuticals IncDirectorSell2,000$6.96$13,920.00View SEC Filing  
8/28/2014Kleanthis G XanthopoulosCEOSell3,505$7.06$24,745.30View SEC Filing  
8/27/2014Isis Pharmaceuticals IncDirectorSell1,500$7.21$10,815.00View SEC Filing  
8/22/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell5,250$6.75$35,437.50View SEC Filing  
8/21/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,500$6.89$17,225.00View SEC Filing  
8/20/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell3,000$7.14$21,420.00View SEC Filing  
8/15/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell1,450$6.98$10,121.00View SEC Filing  
8/14/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell1,750$7.04$12,320.00View SEC Filing  
8/13/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,250$7.02$15,795.00View SEC Filing  
8/8/2014Isis Pharmaceuticals IncDirectorSell1,850$6.80$12,580.00View SEC Filing  
8/7/2014Isis Pharmaceuticals IncDirectorSell2,600$6.66$17,316.00View SEC Filing  
8/6/2014Isis Pharmaceuticals IncDirectorSell3,150$7.08$22,302.00View SEC Filing  
8/1/2014Isis Pharmaceuticals IncDirectorSell2,600$6.21$16,146.00View SEC Filing  
7/31/2014Isis Pharmaceuticals IncDirectorSell1,750$6.42$11,235.00View SEC Filing  
7/30/2014Isis Pharmaceuticals IncDirectorSell1,000$6.60$6,600.00View SEC Filing  
7/25/2014Isis Pharmaceuticals IncDirectorSell1,700$6.55$11,135.00View SEC Filing  
7/24/2014Isis Pharmaceuticals IncDirectorSell1,850$6.81$12,598.50View SEC Filing  
7/23/2014Isis Pharmaceuticals IncDirectorSell1,700$6.88$11,696.00View SEC Filing  
7/18/2014Isis Pharmaceuticals IncDirectorSell5,000$6.80$34,000.00View SEC Filing  
7/17/2014Isis Pharmaceuticals IncDirectorSell5,000$6.58$32,900.00View SEC Filing  
7/16/2014Isis Pharmaceuticals IncDirectorSell3,500$6.59$23,065.00View SEC Filing  
7/11/2014Isis Pharmaceuticals IncDirectorSell1,750$6.48$11,340.00View SEC Filing  
7/10/2014Isis Pharmaceuticals IncDirectorSell4,500$6.69$30,105.00View SEC Filing  
7/9/2014Isis Pharmaceuticals IncDirectorSell1,800$7.08$12,744.00View SEC Filing  
2/4/2014Sanofimajor shareholderBuy1,303,780$7.67$9,999,992.60View SEC Filing  
1/21/2014Neil GibsonInsiderSell4,421$8.09$35,765.8950,000View SEC Filing  
1/17/2014Neil GibsonInsiderSell4,479$8.15$36,503.8550,000View SEC Filing  
1/16/2014Neil GibsonInsiderSell1,100$8.03$8,833.0050,000View SEC Filing  
1/2/2014Kleanthis XanthopoulosCEOSell3,505$7.25$25,411.25View SEC Filing  
10/10/2012Stanley T CrookeDirectorBuy750,000$4.00$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Regulus Therapeutics (NASDAQ RGLS) News Headlines

Source:
DateHeadline
Wedbush Comments on Regulus Therapeutics Inc.s Q4 2019 Earnings (RGLS)Wedbush Comments on Regulus Therapeutics Inc.'s Q4 2019 Earnings (RGLS)
www.americanbankingnews.com - May 21 at 2:02 AM
Regulus Therapeutics (RGLS) Downgraded to "Hold" at Zacks Investment ResearchRegulus Therapeutics (RGLS) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 18 at 10:11 AM
Regulus Therapeutics (RGLS) Receives "Outperform" Rating from WedbushRegulus Therapeutics (RGLS) Receives "Outperform" Rating from Wedbush
www.americanbankingnews.com - May 17 at 4:33 PM
Regulus Therapeutics (RGLS) Lifted to Buy at Zacks Investment ResearchRegulus Therapeutics (RGLS) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - May 16 at 3:01 PM
Regulus Therapeutics (RGLS) Announces  Earnings ResultsRegulus Therapeutics (RGLS) Announces Earnings Results
www.americanbankingnews.com - May 11 at 10:17 PM
BRIEF-Regulus Reports Q1 Loss Per Share $0.15BRIEF-Regulus Reports Q1 Loss Per Share $0.15
www.reuters.com - May 11 at 9:17 AM
Regulus Therapeutics (RGLS) CEO Joseph Hagan on Q1 2018 Results - Earnings Call TranscriptRegulus Therapeutics' (RGLS) CEO Joseph Hagan on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 9:17 AM
Edited Transcript of RGLS earnings conference call or presentation 10-May-18 9:00pm GMTEdited Transcript of RGLS earnings conference call or presentation 10-May-18 9:00pm GMT
finance.yahoo.com - May 11 at 9:17 AM
Regulus Therapeutics (RGLS) Downgraded to Sell at Zacks Investment ResearchRegulus Therapeutics (RGLS) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - May 10 at 5:33 PM
Regulus Reports First Quarter 2018 Financial Results and Pipeline ProgressRegulus Reports First Quarter 2018 Financial Results and Pipeline Progress
finance.yahoo.com - May 10 at 5:22 PM
Regulus: 1Q Earnings SnapshotRegulus: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 5:22 PM
Regulus Therapeutics Inc. (RGLS) Given Average Rating of "Hold" by AnalystsRegulus Therapeutics Inc. (RGLS) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - May 10 at 3:32 PM
Regulus Therapeutics (RGLS) Set to Announce Quarterly Earnings on ThursdayRegulus Therapeutics (RGLS) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - May 4 at 10:12 AM
Regulus Therapeutics (RGLS) Begins Multiple Ascending Dose Study in Healthy Volunteers of RGLS4326 for the ...Regulus Therapeutics (RGLS) Begins Multiple Ascending Dose Study in Healthy Volunteers of RGLS4326 for the ...
www.streetinsider.com - May 3 at 5:22 PM
Regulus to Provide First Quarter 2018 Financial Results on May 10, 2018Regulus to Provide First Quarter 2018 Financial Results on May 10, 2018
finance.yahoo.com - May 3 at 5:22 PM
Regulus launches early-stage study of RGLS4326 in inherited kidney cyst disorder; shares up 3%Regulus launches early-stage study of RGLS4326 in inherited kidney cyst disorder; shares up 3%
seekingalpha.com - May 1 at 5:22 PM
Regulus Initiates Multiple Ascending Dose Study in Healthy Volunteers of RGLS4326 for the Treatment of ADPKDRegulus Initiates Multiple Ascending Dose Study in Healthy Volunteers of RGLS4326 for the Treatment of ADPKD
finance.yahoo.com - May 1 at 5:22 PM
Regulus Therapeutics (RGLS) Set to Announce Earnings on WednesdayRegulus Therapeutics (RGLS) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - April 25 at 7:10 AM
Kathryn J. Collier Joins Regulus Board of DirectorsKathryn J. Collier Joins Regulus Board of Directors
finance.yahoo.com - April 17 at 5:31 PM
Regulus Therapeutics Inc. (RGLS) Given Consensus Rating of "Hold" by BrokeragesRegulus Therapeutics Inc. (RGLS) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 15 at 9:41 AM
Regulus Therapeutics (RGLS) Lowered to "Neutral" at Chardan CapitalRegulus Therapeutics (RGLS) Lowered to "Neutral" at Chardan Capital
www.americanbankingnews.com - April 14 at 10:35 AM
Zacks Investment Research Upgrades Regulus Therapeutics (RGLS) to BuyZacks Investment Research Upgrades Regulus Therapeutics (RGLS) to Buy
www.americanbankingnews.com - April 7 at 6:04 PM
Regulus Therapeutics Inc. Forecasted to Earn FY2018 Earnings of ($0.60) Per Share (RGLS)Regulus Therapeutics Inc. Forecasted to Earn FY2018 Earnings of ($0.60) Per Share (RGLS)
www.americanbankingnews.com - March 30 at 7:04 AM
Regulus Therapeutics (RGLS) Now Covered by B. RileyRegulus Therapeutics (RGLS) Now Covered by B. Riley
www.americanbankingnews.com - March 28 at 8:06 AM
AC Immune (ACIU) and Regulus Therapeutics (RGLS) Financial ComparisonAC Immune (ACIU) and Regulus Therapeutics (RGLS) Financial Comparison
www.americanbankingnews.com - March 27 at 11:24 AM
Regulus to Present at the Needham Healthcare ConferenceRegulus to Present at the Needham Healthcare Conference
finance.yahoo.com - March 20 at 5:34 PM
Edited Transcript of RGLS earnings conference call or presentation 7-Mar-18 10:00pm GMTEdited Transcript of RGLS earnings conference call or presentation 7-Mar-18 10:00pm GMT
finance.yahoo.com - March 18 at 8:48 AM
Wedbush Analysts Lower Earnings Estimates for Regulus Therapeutics Inc (RGLS)Wedbush Analysts Lower Earnings Estimates for Regulus Therapeutics Inc (RGLS)
www.americanbankingnews.com - March 15 at 6:44 AM
Leerink Swann Analysts Boost Earnings Estimates for Regulus Therapeutics Inc (RGLS)Leerink Swann Analysts Boost Earnings Estimates for Regulus Therapeutics Inc (RGLS)
www.americanbankingnews.com - March 12 at 1:52 AM
Regulus Therapeutics (RGLS) Given a $1.00 Price Target by BMO Capital Markets AnalystsRegulus Therapeutics (RGLS) Given a $1.00 Price Target by BMO Capital Markets Analysts
www.americanbankingnews.com - March 8 at 9:24 PM
Head to Head Contrast: Regulus Therapeutics (RGLS) versus GenVec (GNVC)Head to Head Contrast: Regulus Therapeutics (RGLS) versus GenVec (GNVC)
www.americanbankingnews.com - March 8 at 4:13 PM
Regulus Therapeutics (RGLS) Announces  Earnings Results, Beats Expectations By $0.01 EPSRegulus Therapeutics (RGLS) Announces Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - March 7 at 9:14 PM
Regulus Reports Fourth Quarter and Year-end 2017 Financial Results and Pipeline UpdateRegulus Reports Fourth Quarter and Year-end 2017 Financial Results and Pipeline Update
finance.yahoo.com - March 7 at 5:29 PM
Was Regulus Therapeutics Inc’s (NASDAQ:RGLS) Earnings Decline A Part Of Broader Industry Downturn?Was Regulus Therapeutics Inc’s (NASDAQ:RGLS) Earnings Decline A Part Of Broader Industry Downturn?
finance.yahoo.com - March 7 at 8:58 AM
Regulus Therapeutics Inc (RGLS) Shares Sold by Broadfin Capital LLCRegulus Therapeutics Inc (RGLS) Shares Sold by Broadfin Capital LLC
www.americanbankingnews.com - March 3 at 4:55 AM
Ascend Capital LLC Invests $1.05 Million in Regulus Therapeutics Inc (RGLS) StockAscend Capital LLC Invests $1.05 Million in Regulus Therapeutics Inc (RGLS) Stock
www.americanbankingnews.com - March 3 at 4:38 AM
New Research: Key Drivers of Growth for New Media Investment Group, Perficient, Strayer Education, Regulus Therapeutics, Kelly Services, and Insys Therapeutics — Factors of Influence, Major Initiatives and Sustained ProductionNew Research: Key Drivers of Growth for New Media Investment Group, Perficient, Strayer Education, Regulus Therapeutics, Kelly Services, and Insys Therapeutics — Factors of Influence, Major Initiatives and Sustained Production
finance.yahoo.com - March 2 at 8:44 AM
Regulus to Provide Fourth Quarter and Year-end 2017 Financial Results on March 7, 2018Regulus to Provide Fourth Quarter and Year-end 2017 Financial Results on March 7, 2018
finance.yahoo.com - February 28 at 5:29 PM
Regulus Therapeutics Inc (RGLS) Given Consensus Recommendation of "Hold" by AnalystsRegulus Therapeutics Inc (RGLS) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - February 24 at 9:42 AM
WuXi STA and Regulus Announce microRNA Development and Manufacturing CollaborationWuXi STA and Regulus Announce microRNA Development and Manufacturing Collaboration
finance.yahoo.com - February 22 at 8:24 AM
Regulus Therapeutics (RGLS) Set to Announce Quarterly Earnings on WednesdayRegulus Therapeutics (RGLS) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 21 at 2:40 AM
This Mornings Technical Outlook on Biotech Stocks -- Portola Pharma, Protalix BioTherapeutics, Radius Health, and ... - PR Newswire (press release)This Morning's Technical Outlook on Biotech Stocks -- Portola Pharma, Protalix BioTherapeutics, Radius Health, and ... - PR Newswire (press release)
www.prnewswire.com - February 13 at 7:19 AM
Regulus Therapeutics Inc Forecasted to Post FY2022 Earnings of $0.47 Per Share (RGLS)Regulus Therapeutics Inc Forecasted to Post FY2022 Earnings of $0.47 Per Share (RGLS)
www.americanbankingnews.com - February 12 at 9:52 AM
Regulus to Participate in the LEERINK Partners 7th Annual Global ... - PR Newswire (press release)Regulus to Participate in the LEERINK Partners 7th Annual Global ... - PR Newswire (press release)
www.prnewswire.com - February 9 at 7:16 AM
Regulus to Participate in the LEERINK Partners 7th Annual Global Healthcare ConferenceRegulus to Participate in the LEERINK Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 9 at 7:16 AM
Regulus Therapeutics Inc (RGLS) Receives Consensus Rating of "Hold" from AnalystsRegulus Therapeutics Inc (RGLS) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - January 30 at 9:39 AM
Regulus Therapeutics (RGLS) Downgraded by Zacks Investment ResearchRegulus Therapeutics (RGLS) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 25 at 11:48 PM
Regulus Therapeutics (RGLS) Earns "Neutral" Rating from Chardan CapitalRegulus Therapeutics (RGLS) Earns "Neutral" Rating from Chardan Capital
www.americanbankingnews.com - January 20 at 6:28 AM
Regulus Therapeutics (RGLS) Rating Lowered to Hold at Zacks Investment ResearchRegulus Therapeutics (RGLS) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - January 18 at 1:50 PM
UPDATE: Leerink Partners Starts Regulus Therapeutics (RGLS) at Outperform - StreetInsider.comUPDATE: Leerink Partners Starts Regulus Therapeutics (RGLS) at Outperform - StreetInsider.com
www.streetinsider.com - January 5 at 10:02 AM

SEC Filings

Regulus Therapeutics (NASDAQ:RGLS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Regulus Therapeutics (NASDAQ:RGLS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Regulus Therapeutics (NASDAQ RGLS) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.